pd119819' pd119819

PD 119819 is a heterocyclic piperazine. PD 119819 is an extremely selective DA autoreceptor agonist.

PD-1-IN-22 is a potent inhibitor of the programmed cell death-1 (PD-1) programmed cell death-ligand 1 (PD-L1) interaction, with an IC50 of 92.3 nM.

PD-118057 is a potent ether associated (hERG) potassium channel activator that shows no activity against hERG. PD-118057 inhibits the excitability of the membrane by activating the hERG channel. PD-118057 is a potential compound for the treatment of delayed repolarization in inherited or acquired long QT syndrome and congestive heart failure.

PD 0299685 is a potent α2δ ligand of the Ca2+ channel for the treatment of interstitial cystitis.

PD 144418 oxalate is a highly potent and selective sigma 1 (σ1) receptor ligand with a Ki value of 0.08 nM for σ1 and 1377 nM for σ2, exhibiting negligible affinity for other receptors, ion channels, and enzymes, and demonstrating potential antipsychotic activity.

PD-1-IN-17 is an inhibitor of programmed cell death-1 (PD-1). PD-1-IN-17 inhibits 92% splenocyte proliferation at 100 nM.

PD 168568 dihydrochloride (PD 168568 (dihydrochloride)) is an orally active and selective antagonist of D4 dopamine receptor(Ki of 8.8 nM).

PD-1 PD-L1-IN-9, with an IC50 of 3.8 nM, is a potent and orally active inhibitor of the PD-1 PD-L1 interaction. It enhances the immune cells' ability to kill tumor cells and demonstrates significant antitumor activity in vivo in a CT26 mouse model.

PD 198306 is a selective inhibitor of MAPK ERK-kinase (MEK) with antihyperalgesic effects. PD 198306 reduces the Streptozocin-induced increase in the level of active ERK1.

PD 123319 ((S)-(+)-PD 123319) is a potent, selective AT2 angiotensin II receptor antagonist.

PD 128907 is a potent and selective agonist of dopamine D2 and D3 receptors. It is used for studying the role of these receptors in the brain, in roles such as inhibitory autoreceptors that act to limit further dopamine release, as well as release of othe

PD 128042 (CI 976) is a potent, orally active, and selective ACAT inhibitor (IC50: 73 nM) as well as a lysophospholipid acyltransferase (LPAT) inhibitor. CI 976 inhibits Golgi-associated LPAT activity (IC50: 15 μM) and multiple membrane trafficking steps.

PD 169316 is a potent, cell-permeable, and selective inhibitor of p38 MAP kinase.

RMP1-14 is an IgG1-like immunoglobulin and anti-Mouse PD-1 antibody that blocks PD-1 PD-L1 signaling.

PD-161570 is a potent and ATP-competitive human FGF-1 receptor inhibitor with an IC50 of 39.9 nM and a Ki of 42 nM. It also inhibits the PDGFR, EGFR, and c-Src tyrosine kinases with IC50 values of 310 nM, 240 nM, and 44 nM, respectively.

(+)-PD 128907 hydrochloride is an agonist of the D3 dopamine receptor.

PD-168077 maleate is a selective agonist of the dopamine D4 receptor (Ki: 9 nM).

PD 117519 (CI947) is an agonist of the adenosine receptor.

PD 174265 is an effective, selective and reversible inhibitor of epidermal growth factor receptor (EGFR) with an IC50 of 0.45 nM.

PD 90780 is a non-peptide antagonist of nerve growth factor (NGF) that interacts with NGF and prevents it from binding to p75NTR, inhibiting the NGF-p75NTR interaction with IC50s of 23.1 and 1.8 µM in PC12 cells and PC12nnr5 cells, respectively.

PD-166866 is a selective FGFR tyrosine kinase inhibitor.

Methanesulfonato[4,6-bis(diphenylphosphino)phenoxazine](2'-amino-1,1'-biphenyl-2-yl)palladium(II) is a useful organic compound for research related to life sciences and the catalog number is T67254.

PD 099560 is a non-peptide inhibitor of HIV-1 protease, a significant target enzyme in AIDS research.

PD-1 PD-L1-IN-32 (compound A56) is a potent inhibitor of PD-1 PD-L1 with an IC50 value of 2.4 nM, demonstrating significant anticancer activity. It effectively suppresses tumor growth in the hPD-L1 MC38 humanized mouse model and exhibits negligible toxicity to the normal functions of the mice [1].

Methanesulfonato(tricyclohexylphosphine)(2'-amino-1,1'-biphenyl-2-yl)palladium(II) is a useful organic compound for research related to life sciences and the catalog number is T67262.

Josiphos SL-J009-1 Pd G3 has a wide range of applications in life science related research.

Methanesulfonato(diadamantyl-n-butylphosphino)-2'-amino-1,1'-biphenyl-2-yl)palladium(II) is a useful organic compound for research related to life sciences and the catalog number is T64620.

(2-Dicyclohexylphosphino-2',6'-dimethoxybiphenyl)[2-(2'-amino-1,1'-biphenyl)]palladium(II) methanesulfonate is a useful organic compound for research related to life sciences. The catalog number is T64623 and the CAS number is 1445085-82-4.

PD-1/PD-L1-IN 3 TFA inhibits the binding of human PD-1 to PD-Ll with an IC50 of 9 nM.

PD 130908 is an analogue of RSU 1069 with effective hypoxic cytotoxin, but less potent than RSU 1069. Toxicity toward hypoxic tumor cells in vivo is demonstrated by clamping tumors (for 60 min) following administration of PD 130908. Systemic toxicity is s

PD 134922 is a HIV-1 protease inhibitors. Inactivation of the protease prevents infectious virion formation.

PD 114595 is a Benzothiopyrano-indazole cpd. PD 114595 belongs to a class of DNA complexers, PD 114595 has curative properties against murine solid tumor models.

PD 138142 is a water soluble inhibitor of ACAT.

PD-1-IN-17 TFA is a potent inhibitor of programmed cell death-1 (PD-1), effectively inhibiting 92% of splenocyte proliferation at a concentration of 100 nM.

PD-321852 is a small-molecule Chk1 inhibitor, which potentiates gemcitabine-induced clonogenic death in a panel of pancreatic cancer cell lines and evaluated the relationship between endpoints associated with Chk1 inhibition and chemosensitization. Gemcitabine chemosensitization by minimally toxic concentrations of PD-321852 ranged from minimal (<3-fold change in survival) in Panc1 cells to >30-fold in MiaPaCa2 cells. PD-321852 inhibited Chk1 in all cell lines as evidenced by stabilization of Cdc25A; in combination with gemcitabine, a synergistic loss of Chk1 protein was observed in the more sensitized cell lines.

MEK1 inhibitor

PD-L1-IN-1, a powerful PD-L1 inhibitor, demonstrated an IC50 of 115 nM. By forming a robust bond with the PD-L1 protein, PD-L1-IN-1 effectively suppressed tumor growth by enhancing the antitumor immune activity of peripheral blood mononuclear cells in co-cultures with PD-L1 expressing cancer cells (PC9 and HCC827 cells). It significantly elevated the release of interferon γ and induced apoptosis in cancer cells, while exhibiting minimal cytotoxicity in healthy cells [1].

PD-159020 is a non-selective antagonist of ETA ETB (hETA and hETB) with IC50 values of 30 nM and 50 nM, respectively.

PD 131628 is a novel fluoroquinolone that is a bioactive form of PD 131112 or CI-990 for use against anaerobic bacteria.

PD-1 PD-L1-IN-28, an inhibitor of the PD-1 PD-L1 signaling pathway (IC 50 = 0.744 µM), demonstrates promising research potential in tumor immunity. This immune checkpoint inhibitor effectively blocks the interaction within the pathway, offering insights into cancer treatment strategies.

PD-1 PD-L1-IN-27 is a potent inhibitor of PD-1 PD-L1, with an IC50 of 134 nM, and demonstrates antitumor effects with minimal T cell cytotoxicity. It activates CD8+ T cells and mitigates T cell exhaustion [1].

PD 135390 is a HIV-1 protease inhibitors identified by rational selection. Inactivation of the protease prevents infectious virion formation.

PD 130883 is a potent lipophilic quinazoline antifolate.

PD 127443 is a Leukotriene B4 antagonist, it is also a dual inhibitor of cyclooxygenase and 5-lipoxygenase.

PD-1-IN-25 (compound 43) serves as a powerful inhibitor of the PD-1 PD-L1 interaction, boasting an impressive IC50 of 10.2 nM, as measured in the HTRF assay. By impeding PD-1 PD-L1 cellular signaling, PD-1-IN-25 facilitates the activation of CD8+ T cells. Furthermore, it has been shown to delay tumor growth [1].

PD-1 PD-L1-IN-47 (MolPort-001-742-690) is a pH-selective inhibitor of the PD-1 PD-L1 signaling pathway, demonstrating significant affinity for PD-L1 under acidic conditions and lower toxicity. It is utilized in the study of tumors.

PD-1 PD-L1-IN-48 (compound HD10) is an effective inhibitor of the PD-1 PD-L1 interaction, exhibiting an IC50 of 3.1 nM. It plays a vital role in cancer research.

PD-166793 is an orally active, potent and selective MMP inhibitor with inhibitory effects on MMP-2, MMP-3 and MMP-13.PD-166793 ameliorates myocardial ischemia and reperfusion injury in a rat model of heart failure.PD-166793 is an orally active, potent and selective MMP inhibitor with inhibitory effects on MMP-2, MMP-3, and MMP-13.